One patent ruling cut Liquidia in half and sent United Therapeutics up 12%

Wednesday's biggest single-stock moves had almost nothing to do with the inflation report that set the market's tone. They came out of a federal courthouse in Delaware, a fiscal fourth-quarter print that beat on every line and still got sold, and a downgrade with an unusually aggressive price target attached.

The ruling: two claims out of six

The U.S. District Court for the District of Delaware ruled that claims 1 and 14 of United Therapeutics' U.S. Patent No. 11,826,327 — the '327 patent — are valid and infringed by Liquidia's YUTREPIA, a dry-powder inhaled treprostinil product. The remaining four claims asserted against Liquidia were found invalid. The court also denied Liquidia's motion to strike evidence concerning United Therapeutics' ownership of the patent, ruling that Liquidia had adequate notice before trial and failed to object in time.

The claims that survived cover the treatment of pulmonary hypertension associated with interstitial lung disease, or PH-ILD, with inhaled treprostinil — including dry-powder formulations. That is the commercial heart of the matter. By Liquidia's own account, the company will file a supplement with the FDA to remove the PH-ILD indication from YUTREPIA's label, and Investing.com reported that this indication accounts for roughly half of the drug's current market.

Liquidia's chief executive, Roger Jeffs, said in the company's statement:

We respectfully disagree with the Court's decision regarding claims 1 and 14 and are fully prepared to pursue all available appellate options.

Both sides have been directed to submit a proposed form of judgment specifying remedies within one week, and United Therapeutics has asked for injunctive relief in post-trial briefing — which is why the reaction went well beyond a label change. A label supplement is a known quantity. An injunction is not.

The tape reflected that gap. LQDA was halted more than once for volatility, traded near $36.55 in the afternoon — down about 48% at that point — and closed at $30.26, a 57.19% loss on the session and its lowest level in nearly four months. Reuters put the intraday damage at 'nearly 50%' and estimated roughly $3.18 billion of market value at risk if the decline held. The stock's 52-week high is $93.61.

On the other side of a zero-sum ruling, United Therapeutics closed at $541.89, up 12.55%. Reuters reported the move as a 12.3% gain to $540.54 during the session. The decision reinforces the patent protection around Tyvaso, United Therapeutics' inhaled treprostinil franchise and its largest product.

Jabil: beat everything, fell 10%

Jabil reported fiscal fourth-quarter adjusted earnings of $4.40 per share on revenue of $10.62 billion. Analysts polled by LSEG had been looking for $4.07 per share on $9.71 billion. First-quarter and full-year guidance also came in above estimates. The stock closed down 10.03% at $286.86.

There is no contradiction to resolve here so much as a positioning fact to note: Jabil is one of the contract manufacturers that has been re-rated on AI infrastructure demand, and it went into the print at an elevated level. When a stock has already been paid for a good quarter, a good quarter is not news.

Rogers, Moderna and the rest

• Rogers rose 10.73% to $152.99. The circuit-materials maker guided to full-year earnings of about $3.80 per share excluding certain items, against a FactSet consensus near $3.65.
• Moderna fell 5.35% to $192.57 after Citi downgraded the stock to sell. The bank's price target sits roughly 60% below Tuesday's closing price, and its analysts said the current valuation cannot be justified.
• FormFactor was higher by about 8% at midday after Deutsche Bank initiated coverage with a buy rating, citing the semiconductor test company's leverage to AI-driven demand.
• Concentrix rose about 5% on better-than-expected fiscal third-quarter adjusted earnings, even though current-quarter revenue and EPS guidance came in below FactSet estimates and management said its AI transition is pressuring revenue.

What to watch from here

For the Liquidia-United Therapeutics fight, the calendar is short and specific: proposed remedies to the court within a week, then a final judgment that analysts expect in roughly the same window, then whatever appellate path Liquidia takes. The range of outcomes between a narrowed label and an injunction is wide enough that Wednesday's 57% move is better read as the market repricing uncertainty than as a settled verdict on the company.

For the rest of Wednesday's list, the pattern was familiar from the past two weeks: earnings beats are not clearing the bar on their own, analyst actions are moving stocks more than usual, and single-name news is doing far more work than the index level suggests. The S&P 500 moved a quarter of a percent. Four stocks moved more than 10%.